[阿尔茨海默病的新疗法:放射学面临的挑战]
1Klinik für Diagnostische und Interventionelle Neuroradiologie, Universitätsklinikum des Saarlandes, Kirrberger Straße, 66424, Homburg-Saar, Deutschland. alena.haussmann@uks.eu.
Radiologie (Heidelberg, Germany)
|January 29, 2026
概括
单克隆抗体治疗可以减缓阿尔茨海默病的进展. 在治疗期间对粉样蛋白相关成像异常 (ARIA) 的监测对于管理副作用和确保患者安全至关重要.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病是老年人痴呆的主要原因.
- 自2024年以来批准的单克隆抗体疗法提供了一种减缓疾病进展的方法.
- 这些疗法需要仔细监测特定副作用.
研究的目的:
- 强调在阿尔茨海默病单克隆抗体治疗期间监测粉样蛋白相关成像异常 (ARIA) 的重要性.
- 讨论ARIA的管理影响,包括潜在的治疗暂停.
- 强调大脑粉样血管病变 (CAA) 和其炎症形式 (CAA-I) 的差异诊断.
主要方法:
- 对阿尔茨海默病单克隆抗体治疗当前治疗指南的审查.
- 分析与ARIA相关的磁共振成像 (MRI) 发现.
- 考虑差异诊断,包括CAA和CAA-I.
主要成果:
- 单克隆抗体治疗可以减缓阿尔茨海默病的进展.
- 与粉样蛋白相关的成像异常 (ARIA),包括 (ARIA-E) 和出血 (ARIA-H),是关键的MRI变化.
- 治疗调整,包括暂停治疗,是基于ARIA的严重程度.
结论:
- 在单克隆抗体治疗期间,定期对ARIA进行MRI监测至关重要.
- 对阿尔茨海默病治疗的管理决策必须考虑ARIA.
- 大脑粉样血管病变 (CAA) 和CAA-I是差异诊断中的重要考虑因素.
相关概念视频
Alzheimer's Disease: Treatment
946
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
946
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
485
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
485
Radiological Investigation I: X-ray and CT
1.2K
Radiological investigations, including X-rays and computed tomography (CT) scans, are critical for diagnosing and evaluating various medical conditions. These imaging techniques provide valuable insights into the body's internal structures, aiding in the detection of abnormalities, assessment of disease progression, and development of treatment strategies. This article delves into two primary radiological investigations, chest X-rays and CT scans, outlining their purpose, procedures, and...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
534
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
534


